Pharmacotherapy of Alzheimer's (AD) and Parkinson's disease (PD) is stillinergic drugs that can provide continuous dopaminergic stimulation symptomatic. In the initiation phase of the pharmacotherapy the dose of the majority of these drugs is kept low and it should be gradually increased until the optimal clinical effect is reached. Cholinesterase inhibitors such asdonepezil, galantamine, and rivastigmine represent the first class of drugs approved for the treatment of mild to moderate AD, while memantine, a NMDA receptor antagonist, is recommended for the treatment of severe AD. Dopaminergic drugs, amongst which levodopa is the most effective, are the first class drugs approved for the treatment of PD. The treatment with levodopa is recommended for older patients, while the dopamine agonists such as pramipexol and ropinirol are used for younger patients. Progressive neurodegeneration results in narrower therapeutic window of levodopa. Consequently, even minor fluctuations in levodopa plasma concentrations can berelated to the occurrence of motor complications. Motor complications can bereduced by using new delivery systems of dopaminergic drugs that can providecontinuous dopaminergic stimulation.